

REMARKS

Claims 1-10 and 14-22 are in this application. Claims 11-13 have been cancelled.

Claims 1 and 14 are being amended to replace "spouse" with "male mate". Support for this is found on the top of page 10 where it is stated "when the woman is pregnant again with same spouse" it is understood that the spouse is a male mate.

Claims 14 and 17 are being amended and are now independent claims. Claims 3, 6 to 9, 15-16 and 18-22 are being amended to replace the phrase "characterized by" with "wherein."

The Examiner requires restriction between the groups of invention identified as:

Group I-claims 1-10 drawn to a composition comprising a fibronectin gene of a male;

Group II- claims 11 and 12 drawn to using a substance capable of lowering in vivo level of antinuclear antibody to make a medicament; and

Group III-claims 13-22 drawn to a method of treatment using a substance capable of lowering the in vivo level of antinuclear antibody.

This restriction requirement is respectfully traversed. It is applicants' position that all of the claims should be searched and examined in this application. In view of the amendments to claims 14 and 17 in which chromosome No. 2 or fragments thereof are derived from a male, the claims of Groups I and III are provisionally elected to be examined in this application. If the Examiner does not agree that both sets of claims should be examined in this application, the claims of Group III, claims 13-22 are provisionally elected.

All rights to file one or more divisional applications for the subject matter disclosed or

claimed in this application and not presently claimed is preserved.

It is submitted that the application is in condition for allowance and favorable consideration is respectfully requested.

Respectfully submitted,



JANET I. CORD
LADAS & PARRY LLP
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO.33778 (212)708-1935